Prevalence of Helicobacter Pylori Infection in Patients with Upper Gastrointestinal Bleeding

Mustafa Mohamed Abdulateef,Rushdi Abdulhameed Abdulameer,Laith Hikmet Muhsun

doi:10.11648/j.ejpm.20190706.16

Mustafa Mohamed Abdulateef, Rushdi Abdulhameed Abdulameer + Show 1 more

Open Access

https://doi.org/10.11648/j.ejpm.20190706.16

Copy DOI

Journal: European Journal of Preventive Medicine	Publication Date: Jan 1, 2019
License type: cc-by

Abstract

Helicobacter pylori is one of the most common chronic bacterial infections in humans, with more than 50% of the world’s population infected with these bacteria It is a micro-aerophilic, slow-growing, gram-negative spiral bacterium that colonizes the mucous lining of the human stomach. Warren and Marshall first cultured and identified the organism as Campylobacter pylori in 1982. In 1989, it was renamed and recognized to be associated closely with antral gastritis (gastric and duodenal ulcers in adults and children). Further evidence supported a link between chronic gastritis of Helicobacter pylori (H. pylori) infection in adults and malignancy, specifically gastric lymphoma and adenocarcinoma. Infection with this bacterium has been identified as a cause of gastritis, peptic ulcer disease, and gastric mucosa-associated lymphoid tissue lymphoma. Globally, the prevalence of H. pylori-related infection is high compared to any other infectious diseases, and the rate of prevalence much higher in developing countries than in developed nations.

Highlights

Helicobacter pylori is one of the most common chronic bacterial infections in humans, with more than 50% of the world’s population infected with these bacteria [1]
There was no significant association between NSAIDs consumption and UGITB among those who were H. pylori infection positive or not
This study show prevalence of H. pylori infection in patients with UGIT bleeding was 68.5% (48/70), the high prevalence was probably because the study was done among only symptomatic patients (UGITB symptoms)

Summary

Introduction

Helicobacter pylori is one of the most common chronic bacterial infections in humans, with more than 50% of the world’s population infected with these bacteria [1]. A negative urease test does not necessarily exclude H. pylori infection in an individual taking anti-secretory medication, a common scenario in patients referred for EGD. The sensitivity of the test is 88% to 95%, with false-negative results reported in patients taking anti-secretory therapy such as PPIs [14, 19], bismuth, or antibiotics.

Results

Conclusion